Citadel Advisors
SPRY icon

Citadel Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Citadel Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Sell
20,600
-31,400
-60% -$270K ﹤0.01% 12261
2026
Q1 		$418K Buy
52,000
+35,200
+210% +$337K ﹤0.01% 9735
2025
Q4 		$196K Buy
16,800
+2,000
+14% +$19.4K ﹤0.01% 11065
2025
Q3 		$149K Sell
14,800
-3,300
-18% -$47.4K ﹤0.01% 11537
2025
Q2 		$316K Sell
18,100
-10,800
-37% -$156K ﹤0.01% 9697
2025
Q1 		$364K Buy
28,900
+17,200
+147% +$207K ﹤0.01% 9159
2024
Q4 		$123K Buy
11,700
+9,100
+350% +$127K ﹤0.01% 11143
2024
Q3 		$37.7K Sell
2,600
-17,500
-87% -$208K ﹤0.01% 12208
2024
Q2 		$171K Sell
20,100
-5,100
-20% -$45.3K ﹤0.01% 10155
2024
Q1 		$258K Sell
25,200
-6,800
-21% -$50.7K ﹤0.01% 9797
2023
Q4 		$175K Sell
32,000
-17,100
-35% -$74.9K ﹤0.01% 10140
2023
Q3 		$186K Buy
49,100
+9,100
+23% +$59.7K ﹤0.01% 10039
2023
Q2 		$268K Buy
40,000
+2,400
+6% +$16K ﹤0.01% 9286
2023
Q1 		$245K Sell
37,600
-2,000
-5% -$15.4K ﹤0.01% 9800
2022
Q4 		$338K Buy
39,600
+27,400
+225% +$178K ﹤0.01% 9062
2022
Q3 		$64K Sell
12,200
-49,100
-80% -$242K ﹤0.01% 11451
2022
Q2 		$260K Buy
+61,300
New +$214K ﹤0.01% 10137

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors's SPRY Position: Q2 2026 in Review

Citadel Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 70% in Q2 2026, selling an estimated $10.7M and leaving 531,063 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #5012.

Citadel Advisors first reported a position in SPRY in Q4 2020 and has held it in 22 quarters since. The position peaked at $39.1M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Citadel Advisors held 531,063 shares of ARS Pharmaceuticals worth $4.25M as of Q2 2026.
  • Citadel Advisors sold 1,242,125 ARS Pharmaceuticals shares in Q2 2026, an estimated $10.7M.
  • ARS Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5012 holding.
  • Citadel Advisors first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's ARS Pharmaceuticals position peaked at $39.1M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.